Entrepreneur Leila Janah died from complications of epithelioid sarcoma. Here's what that is
Leila Janah, a fierce entrepreneur who worked to help those living below the poverty line, died in January from complications of epithelioid sarcoma -- a form of cancer. (Source: CNN.com - Health)
Source: CNN.com - Health - February 2, 2020 Category: Consumer Health News Source Type: news
Treatment Combination May Be Effective for Antitumor Activity in Advanced Sarcoma
The combination of talimogene laherparepvec and pembrolizumab was associated with antitumor activity across a range of sarcoma histologic subtypes in this phase II clinical trial. (Source: CancerNetwork)
Source: CancerNetwork - January 28, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
Title: Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid SarcomaCategory: Health NewsCreated: 1/24/2020 12:00:00 AMLast Editorial Review: 1/27/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 27, 2020 Category: Cancer & Oncology Source Type: news
Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
Approval marks the first for a drug to treat this rare soft tissue sarcoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 25, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news
Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
FRIDAY, Jan. 24, 2020 -- Tazverik (tazemetostat) has received the first approval for treatment of adults and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that cannot be resected, the U.S. Food and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 24, 2020 Category: General Medicine Source Type: news
FDA approves tazemetostat for advanced epithelioid sarcoma
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Tazemetostat (Tazverik) for Rare Sarcoma FDA Approves Tazemetostat (Tazverik) for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Tazemetostat (Tazvenik) for Rare Sarcoma FDA Approves Tazemetostat (Tazvenik) for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Tazemetostat, First Drug for Rare Sarcoma FDA Approves Tazemetostat, First Drug for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves first treatment option specifically for patients with epithelioid sarcoma
Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ). (Source: World Pharma News)
Source: World Pharma News - January 24, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
FDA Approves Tazemetostat for the Treatment of Epithelioid Sarcoma
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the methyltransferase inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA approves local biotech's first rare-cancer drug
The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc.
Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the drug, Tazverik, to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer.
Tazverik is the fi rst drug specifically designed for the cancer, which is diagnosed in 150 to 200 people each year, according… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2020 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
FDA approves local biotech's first rare-cancer drug
The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc.
Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the drug, Tazverik, to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer.
Tazverik is the fi rst drug specifically designed for the cancer, which is diagnosed in 150 to 200 people each year, according… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 23, 2020 Category: Biotechnology Authors: Allison DeAngelis Source Type: news
FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 23, 2020-- Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 23, 2020 Category: Drugs & Pharmacology Source Type: news
B cells: New allies in sarcoma immunotherapy?
(INSERM (Institut national de la sant é et de la recherche m é dicale)) How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer? An international team led by Wolf Herv é Fridman with researchers from Inserm, Sorbonne Universit é and Universit é de Paris, has shown that B cells also play a major role in predicting of patient's response to immunotherapy. Their findings, to be published in Nature, pave the way for the personalization of treatments for patients with soft tissue sarcomas. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 15, 2020 Category: International Medicine & Public Health Source Type: news
